Gastric Antral Vascular Ectasia during the Treatment of Chronic Myelogenous Leukemia with Imatinib Mesylate

This report describes three patients with chronic myelogenous leukemia who developed gastric antral vascular ectasia (GAVE) during treatment with imatinib mesylate (IM). Cessation and/or switching from IM to nilotinib resulted in the alleviation of gastrointestinal (GI) bleeding and ectatic lesions....

Full description

Saved in:
Bibliographic Details
Published inInternal medicine (Tokyo, 1992) Vol. 55; no. 1; pp. 69 - 72
Main Authors Narukawa, Kensuke, Kakihana, Kazuhiko, Fujiwara, Takashi, Kobayashi, Takeshi, Doki, Noriko, Sakamaki, Hisashi, Ohashi, Kazuteru
Format Journal Article
LanguageEnglish
Published 30.12.2015
Online AccessGet full text

Cover

More Information
Summary:This report describes three patients with chronic myelogenous leukemia who developed gastric antral vascular ectasia (GAVE) during treatment with imatinib mesylate (IM). Cessation and/or switching from IM to nilotinib resulted in the alleviation of gastrointestinal (GI) bleeding and ectatic lesions. Furthermore, GI bleeding recurred after the re-administration of IM in one patient. Thus, we consider that the occurrence of GAVE in our patients was induced by IM. Although the precise mechanism of IM-GAVE is not understood, all patients took at least 400 mg/day of IM at the onset of GAVE. Thus, higher doses of IM ( greater than or equal to 400 mg/day) may be a risk factor for IM-GAVE.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
content type line 23
ObjectType-Feature-2
ISSN:0918-2918
1349-7235